

mesothelioma

1550

CHEMOTHERAPY OF MALIGNANT PLEURAL MESOTHELIOMA DOES NOT PRECLUDE USE OF CHECK-POINT BLOCKADE

A. Curioni Fontecedro¹, V. Cecconi², E. Felley Bosco³, I. Schmitt-Opitz³, W. Weder³, R.A. Stahel⁴, M. van den Broek², V. Tischler⁵

¹Department of Oncology, University Hospital Zürich, Zurich, Switzerland

²Experimental Immunology, University of Zurich, Zurich, Switzerland

³Department of Thoracic Surgery, University Hospital Zürich, Zurich, Switzerland

⁴Clinic for Oncology, University Hospital Zuerich, Zurich, Switzerland

⁵Institute of Surgical Pathology, University Hospital Zürich, Zurich, Switzerland

Background: Mesothelioma is an aggressive cancer with short survival and urgent need of new therapeutic options. Based on preclinical data, immunotherapy may be a promising approach to treat this disease. However, it is not known whether

chemotherapy influences the expression of molecules targeted by check-point blockade such as Programmed Death Receptor 1 (PD-1), its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), CD275 (ICOS-L) and CD276 (B7-H3).

Methods: We therefore analyzed the expression of HLA-I, II, PD-L1, ICOS-L and B7-H3 in 88 tumor samples derived from untreated mesothelioma patients using a Tissue Microarray (TMA). In addition, we evaluated the expression of these molecules on matching whole tumor sections from 10 patients before and after chemotherapy.

Finally, we analyzed the expression of HLA-I, II, PD-L1, ICOS-L and B7-H3 on mesothelioma cell lines, upon treatment with cisplatin/pemetrexed or gemcitabine.

Results: We found that tumor cells expressed HLA-I in 79/88 samples (90%); HLA-II in 14/88 samples (16%), PD-L1 in 14/88 samples (16%), ICOS-L in 45/88 samples (50%) and B7-H3 in 55/80 samples (69%) on TMA. We observed no down-regulation of any of the investigated molecules on matching whole tumor sections from patients before and after treatment with cisplatin/pemetrexed. This result was also confirmed using mesothelioma cell lines.

Conclusions: Our results demonstrate that chemotherapy of mesothelioma does not preclude use of check-point blockade.

Disclosure: All authors have declared no conflicts of interest.